S095025 / Servier, Palvella Therapeutics - LARVOL DELTA

Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (Pieris Press Release) - "Pieris and Servier continue to enroll the escalation portion of the phase 1/2 study of PRS-344/S095012...for the treatment of solid tumors, for which Pieris holds full U.S. rights and will receive royalties on ex-U.S. sales by Servier. The companies expect to present data from the study at a medical meeting in 2023. Additionally, Servier is continuing development of PRS-352/S095025, an OX40/PD-L1 bispecific Mabcalin compound."

Enrollment status • P1/2 data • Pipeline update • Oncology • Solid Tumor

The anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1-dependent manner (AACR 2022) - "We provide here the preclinical characterization of the fusion protein PRS-352/S095025, a bispecific molecule composed of a PD-L1 blocking moiety and an Anticalin protein agonizing OX40. In vitro, this molecule showed the desired MoA, PD-L1 blocking and potent OX40 agonism driven by binding to PD-L1, with superior activity to a clinical stage OX40 agonist."

IO biomarker • Late-breaking abstract • Oncology • Solid Tumor • CD4 • PD-L1 • TNFA

Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update (Yahoo Finance) - "Pieris and Servier continue development of PRS-344 and PRS-352. Pieris anticipates filing an IND application for PRS-344, a 4-1BB/PD-L1 bispecific, next year. The Company holds exclusive commercialization rights for PRS-344 in the United States and will receive royalties on ex-U.S. sales by Servier for this program. Pieris is also focused on completing the non-GLP preclinical work for PRS-352, a preclinical-stage program addressing undisclosed targets, and expects to hand it over to Servier in the fourth quarter of this year."

Commercial • IND • Oncology